



PRESS RELEASE

LFB S.A. increases its capital by 230 million euros

Les Ulis, October 12 2015 – Designed to support the development of the LFB group, this capital increase was voted by LFB S.A.’s Board of Directors on 18th September, and was approved in General meeting of shareholders on 2nd October. It will be wholly subscribed by the French State which is the unique shareholder of LFB S.A.

The release schedule is based on four successive steps between the first subscription before 16th October 2015, for 60 million euros, and the fourth subscription planned for April 2018 latest. At the end of the operation, the authorized capital of LFB S.A. will be of 280 million euros (280 000 000 euros), falling into five millions and six hundreds of thousands (5 600 000) shares of fifty euros (50 euros) each.

This capital increase aims at supporting the development of the LFB group for the years to come, namely with the financing of a new manufacturing facility for plasma-derived medicinal products. Located in the north of France, this “next generation” plant is to start in 2020 and allow LFB to triple within the next ten years, its global production capacity for plasma-derived medicinal products. It will also upgrade the production costs in order to strengthen the group’s competitiveness in a highly technological field, and meet the highest global standards, allowing LFB to increase its international sales.

About the LFB group. *The LFB group (www.lfb.fr) is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Hemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.*

The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group markets its products in more than 40 countries around the world with a global turnover of € 501.9 million in 2014. www.lfb.fr

Contact LFB S.A

Sandrine Charrières – Executive VP Corporate Communications
Phone: +33 (1) 69 82 72 80
email : charrieres@lfb.fr

Media relations contact: Jeanne Bariller

Havas Worldwide
Phone : +33 (6) 15 51 49 40
jeanne.bariller@havasww.com